XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
  Hearing Imapirment
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

ENT Channel
subscribe to ENT newsletter

Latest Research : ENT

   DISCUSS   |   EMAIL   |   PRINT
Role of Folic Acid in Treatment of Laryngeal Leucoplakia
Jun 13, 2006 - 2:26:00 AM, Reviewed by: Dr. Priya Saxena

"our complete response rate is lower than the one reported in a smaller population, is characterized by a lower grade of toxicity,"

 
Folic acid supplements may prevent cancer progression and promote regression of disease, according to a new study. Published in the July 15, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the small study found that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements. In 12 of 31 responders, there was no evidence of the original lesion. Folate levels in the patients' blood also increased significantly from baseline while homocysteine levels decreased significantly. This study provides data to support the hypothesis that folate insufficiency is a risk factor for cancer progression.

Folate deficiency is the most common vitamin deficiency in the United States. Folate is a naturally occurring B vitamin (B-9) found abundantly in fresh vegetables and fruits. Folic acid is its more stable synthetic form found in dietary supplements and fortified foods. At the biochemical level, folate is incorporated into coenzymes that are essential in facilitating a variety of reactions in nucleic acid and amino acids metabolism. Some of which are critical to healthy life, such as DNA synthesis, DNA repair, and converting homocysteine to methionine. The latter is particularly important because excess homocysteine is linked to chronic health problems, such as cancer and cardiovascular disease.

Animal and human studies have increasingly demonstrated associations between folate deficiency, serum homocysteine elevations, and a variety of cancers. Some studies have suggested folate supplementation or at least a high folate dietary intake may protect against some cancers. This body of evidence suggests folate to be an effective chemopreventive drug. Other chemopreventive drugs are being tested, and while the retinoids demonstrate the most promise, they are highly toxic. Giovanni Almadori, M.D. of the Institute of Otolaryngology, Universit� Cattolica del Sacro Cuore, Policlinico A. Gemelli in Rome, Italy and colleagues investigated the efficacy of folic acid dietary supplementation to treat precancerous lesion and prevent cancer.

The investigators enrolled 43 patients with untreated laryngeal leucoplakia and treated them with folic acid (5mg three times a day) and evaluated the progression of leucoplakia every 30 days for six months.

Over six months of treatment, 12 patients (28 percent) had complete resolution of their leucoplakia lesions; 19 patients (44 percent) had reduction of 50 percent or more in the size of their lesions and 12 patients (28 percent) had no response. Mean folate levels increased and mean homocysteine levels decreased significantly. There were no moderate or severe adverse events reported.

Comparison to another promising chemopreventive drug regimen that includes a retinoid, "our complete response rate is lower than the one reported in a smaller population," the authors write. Nevertheless, folate "is characterized by a lower grade of toxicity," and there was no progression of disease.

These results suggest, according to the researchers, "folate supplementation, alone or in combination with other chemopreventive drugs, could effectively reduce the risk of progression in an already genetically altered mucosa, especially in patients with hypofolatemia."
 

- "Pilot Phase IIA Study for Evaluation of the Efficacy of Folic Acid in the Treatment of Laryngeal Leucoplakia," Giovanni Almadori, Francesco Bussu, Pierluigi Navarra, Jacopo Galli, Gaetano Paludetti, Bruno Giardina, Maurizio Maurizi, CANCER; Published Online: June 12, 2006 (DOI: 10.1002/cncr.22003); Print Issue Date: July 15, 2006.
 

www.interscience.wiley.com

 
Subscribe to ENT Newsletter
E-mail Address:

 



Related ENT News

UK researcher identifies brain region responsible for spatial hearing
Boosting local immunity in nose can help treat chronic sinusitis
Acidic mammalian chitinase gene linked to recurrent sinusitis
Beta-actin mutations linked to deafness and dystonia
Role of Folic Acid in Treatment of Laryngeal Leucoplakia
Hyperactivity, attention deficit, sleepiness, and ADHD often improves after tonsillectomy - Study
New vaccine against ear infection
Middle cranial fossa approach preserves hearing in acoustic neuroma patients
Aldosterone linked to good hearing as we age
Antibiotic telithromycin linked to liver damage


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us